Eric Coldwell
Stock Analyst at Baird
(4.01)
# 570
Out of 5,117 analysts
182
Total ratings
61.68%
Success rate
8.31%
Average return
Main Sectors:
Stocks Rated by Eric Coldwell
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MCK McKesson | Maintains: Outperform | $873 → $927 | $828.26 | +11.92% | 18 | Nov 6, 2025 | |
| CRL Charles River Laboratories International | Upgrades: Outperform | $178 → $199 | $203.66 | -2.29% | 15 | Nov 6, 2025 | |
| IQV IQVIA Holdings | Upgrades: Outperform | $224 → $258 | $226.92 | +13.70% | 19 | Oct 29, 2025 | |
| FTRE Fortrea Holdings | Maintains: Outperform | $9 → $14 | $17.40 | -19.54% | 9 | Sep 3, 2025 | |
| ICLR ICON Public Limited Company | Maintains: Outperform | $222 → $224 | $182.84 | +22.51% | 22 | Sep 2, 2025 | |
| DGX Quest Diagnostics | Downgrades: Neutral | $194 | $175.94 | +10.26% | 11 | Aug 25, 2025 | |
| CAH Cardinal Health | Maintains: Outperform | $197 → $203 | $208.29 | -2.54% | 13 | Aug 13, 2025 | |
| OMI Owens & Minor | Maintains: Outperform | $10 → $7 | $2.77 | +152.71% | 19 | Aug 12, 2025 | |
| LH Labcorp Holdings | Maintains: Outperform | $290 → $302 | $253.89 | +18.95% | 14 | Jul 25, 2025 | |
| MEDP Medpace Holdings | Maintains: Neutral | $313 → $490 | $567.56 | -13.67% | 19 | Jul 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $14 → $16 | $10.25 | +56.10% | 10 | Feb 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $35 → $45 | $60.81 | -26.00% | 2 | Jun 26, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $62 → $66 | $79.61 | -17.10% | 7 | May 7, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $67 → $46 | $1.13 | +3,988.89% | 4 | Nov 10, 2017 |
McKesson
Nov 6, 2025
Maintains: Outperform
Price Target: $873 → $927
Current: $828.26
Upside: +11.92%
Charles River Laboratories International
Nov 6, 2025
Upgrades: Outperform
Price Target: $178 → $199
Current: $203.66
Upside: -2.29%
IQVIA Holdings
Oct 29, 2025
Upgrades: Outperform
Price Target: $224 → $258
Current: $226.92
Upside: +13.70%
Fortrea Holdings
Sep 3, 2025
Maintains: Outperform
Price Target: $9 → $14
Current: $17.40
Upside: -19.54%
ICON Public Limited Company
Sep 2, 2025
Maintains: Outperform
Price Target: $222 → $224
Current: $182.84
Upside: +22.51%
Quest Diagnostics
Aug 25, 2025
Downgrades: Neutral
Price Target: $194
Current: $175.94
Upside: +10.26%
Cardinal Health
Aug 13, 2025
Maintains: Outperform
Price Target: $197 → $203
Current: $208.29
Upside: -2.54%
Owens & Minor
Aug 12, 2025
Maintains: Outperform
Price Target: $10 → $7
Current: $2.77
Upside: +152.71%
Labcorp Holdings
Jul 25, 2025
Maintains: Outperform
Price Target: $290 → $302
Current: $253.89
Upside: +18.95%
Medpace Holdings
Jul 23, 2025
Maintains: Neutral
Price Target: $313 → $490
Current: $567.56
Upside: -13.67%
Feb 27, 2025
Maintains: Outperform
Price Target: $14 → $16
Current: $10.25
Upside: +56.10%
Jun 26, 2020
Maintains: Neutral
Price Target: $35 → $45
Current: $60.81
Upside: -26.00%
May 7, 2020
Maintains: Neutral
Price Target: $62 → $66
Current: $79.61
Upside: -17.10%
Nov 10, 2017
Maintains: Outperform
Price Target: $67 → $46
Current: $1.13
Upside: +3,988.89%